Biomarx
PrivateLast Round
Pre Seed
Jan 5, 2026
Total Funding Raised
$930,000
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Biomarx operates in Healthcare & Life Sciences and is based in Belfast. Its latest recorded funding round was a Pre Seed round in January 2026.
Biomarx is a medtech company that provides a platform for rapid, reliable, and affordable molecular diagnostic solutions.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biomarx Comparables
Compare Biomarx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avitia | 78% | |
| Pillar Biosciences | 76% | |
| Biocartis Group NV | 74% |
For institutional investors. Book with your work email.
Biomarx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Pre Seed | Jan 5, 2026 | ||||
| Seed | Oct 13, 2025 |
For institutional investors. Book with your work email.
Biomarx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Clarendon Fund Managers | Pre Seed |
| Deepbridge Capital | Pre Seed |
| University of Strathclyde | Pre Seed |
| Techstart Ventures | Pre Seed |
| SFC Capital | Pre Seed |
| Scottish Investment Bank (Scottish Enterprise) | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 231% MoM.
- Jan 5, 2026
$948K round led by SFC Capital and Clarendon Fund Managers.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withNov 12, 2026
Biomarx partners with University of Strathclyde to advance liquid biopsy technology, with University of Strathclyde providing research facilities, intellectual property support, regulatory quality assistance, and a doctoral research programme in the United Kingdom in exchange for an equity stake.
For institutional investors. Book with your work email.
Biomarx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Biomarx's valuation, stock price, and market status.
Is Biomarx a public or private company?
Biomarx is a private company.
What is the current stock price of Biomarx?
Biomarx is a private company, so its shares have no public market price. Caplight tracks Biomarx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Biomarx worth (valuation)?
Valuation information for Biomarx is not publicly available.
Can I buy Biomarx stock?
Biomarx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Biomarx's last funding round?
Biomarx's most recent funding round was Pre Seed on January 5, 2026.
Who are the main investors in Biomarx?
Key investors in Biomarx include Clarendon Fund Managers, SFC Capital.
Will Biomarx IPO soon?
No public IPO plans have been announced for Biomarx.
How can I track Biomarx secondary market activity?
Caplight tracks bids, offers, and trades in Biomarx's shares on secondary markets.